Related Experiment Videos
Regulation and role of TGF beta production in breast cancer
1Department of Clinical Chemistry, University Hospital Eppendorf, Hamburg, Germany.
Abstract:
The influence of antiestrogens on the secretion of transforming growth factor beta (TGF beta) proteins that have an autoinhibitory potential for human cancer cells was studied in the estrogen-responsive human breast cancer cell line, MCF-7: Antiestrogens induce the secretion of TGF beta-1 via a nontranscriptional pathway; TGF beta-1 itself induces TGF beta-2 by a direct transcriptional mechanism; and TGF beta-2 is a marker of antiestrogen action. This hypothesis was confirmed in a clinical study with 18 patients with advanced metastatic breast cancer. TGF beta-2 plasma levels were measured before and after 4 weeks of treatment with tamoxifen. In the majority of patients who responded to the treatment, increasing TGF beta-2 concentrations were seen under therapy. Patients who did not respond did not show changes in the TGF beta-2 plasma level after 4 weeks of treatment. These results suggest that the sequential analysis of TGF beta-1 in plasma before and under treatment with tamoxifen allows the early identification of patients with antiestrogen resistance.
Insights
Antiestrogens impact transforming growth factor beta (TGF-β) secretion in breast cancer. Measuring TGF-β-2 levels can predict patient response to antiestrogen therapy, aiding early identification of resistance.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Antiestrogens influence transforming growth factor beta (TGF-β) secretion in human cancer cells.
- TGF-β proteins possess autoinhibitory potential for cancer cell growth.
Purpose of the Study:
- To investigate the influence of antiestrogens on TGF-β secretion in breast cancer.
- To determine if TGF-β-2 can serve as a marker for antiestrogen action and treatment response.
Main Methods:
- Utilized the estrogen-responsive human breast cancer cell line MCF-7.
- Conducted a clinical study measuring TGF-β-2 plasma levels in 18 metastatic breast cancer patients before and after tamoxifen treatment.
Main Results:
- Antiestrogens induce TGF-β-1 secretion via a non-transcriptional pathway.
- TGF-β-1 transcriptionally induces TGF-β-2, a marker of antiestrogen action.
- Increased TGF-β-2 plasma levels correlated with treatment response in patients receiving tamoxifen.
Conclusions:
- TGF-β-2 is a reliable marker for assessing antiestrogen therapy efficacy.
- Sequential analysis of TGF-β-2 in plasma can facilitate early identification of antiestrogen resistance in breast cancer patients.